Lord Moynihan of Chelsea

Lord Moynihan of Chelsea's full title is The Lord Moynihan of Chelsea OBE. His name is Jonathan Patrick Moynihan, and he is a current member of the House of Lords.

Registered Interests

Registered Interests for Lord Moynihan of Chelsea.

The Register is updated continuously throughout each sitting day and at regular intervals on other days.

Category 2: Shareholdings etc. (a)

  • JoCR Productions Limited (artistic and related productions)
  • Vos Amis Limited (investment advice, personal services and real estate)

Category 2: Shareholdings etc. (b)

  • Plaquetec Limited (research and commercial development concerning coronary heart disease)
  • Asset Match (private market trading platform)
  • Brewdog (brewing)
  • Libero Pharma (research and commercial development in opioid receptor antagonism)
  • Map of Agriculture (global data platform connecting farms and industry)
  • Ptarmigan Planning Ltd (strategic land planning)
  • WebTel Mobi (specialised network provider)
  • Shelley Media (Ingenious Broadcasting) (investment company for independent film and television programmes)
  • Deepbridge Life Sciences (investment in healthcare innovation companies)
  • FibaTech Industries (production of fibre-reinforced polymers)
  • Well Safe Solutions (oil well decommissioning) (shareholding and corporate debt security)
  • Money Hub (financial services app)
  • Sonorous NV (research and commercial development in symptomatic cerebral venous diseases)
  • Itemize Corp (financial transaction processing)
  • Terrestrial Energy (molten salt and fission technology)
  • HzO (nanocoating solutions for electronics)
  • Candel Therapeutics (research and development in viral immunotherapies)
  • Journey Medical Corp (research and development in skin care) (interest ceased 11 September 2024)
  • Evotec (research and development in effective therapeutics) (interest ceased 26 February 2025)
  • Fortress Biotech (research and development in biopharmaceuticals)
  • Mustang Bio (research and development in next generation therapies)
  • TG Therapeutics (research and development in B-cell biologies)
  • Astra Zeneca (pharmaceuticals) (interest ceased 28 November 2024)
  • BP (oil) (interest ceased 2 September 2024)
  • Nestle (food and beverages) (interest ceased 26 February 2025)
  • Shell (oil) (interest ceased 26 February 2025)
  • Schlumberger (global technology) (interest ceased 26 February 2025)
  • Total Energies (oil) (interest ceased 26 February 2025)
  • Sabby Volatility Fund (hedge fund)
  • CQS Credit Multi Asset Fund (research-driven credit strategies hedge fund)
  • East Rocky LLP (hedge fund)
  • Cerus Endovascular (sold to Stryker in May 2023) (research and development in interventional neuroradiology devices)
  • Guinness Ventures (investment in early-stage businesses)
  • Adaptimmune (cell therapy for cancer) (interest ceased 14 April 2025)
  • Avenue Therapeutics (research and development in neurological diseases)
  • SAB Biotherapeutics (biotechnology)
  • Cyngn Inc (autonomous vehicle technology for industrial fleets)
  • Pantheon (oil and gas) (interest ceased 26 February 2025)
  • Oryx International Growth Fund Limited
  • Valorum Biologics (pharmaceuticals)

Category 2: Shareholdings etc. (c)

  • Apax Global Alpha Limited (private equity investment trust) (interest ceased 26 February 2025)
  • Neuberger Berman (private equity investment trust) (interest ceased 26 February 2025)
  • HG Capital Trust (private equity investment trust) (interest ceased 26 February 2025)
  • HarbourVest (private equity investment trust) (interest ceased 26 February 2025)

Category 3: Land and property

  • Flat in London SW3 from which rental income is received (interest ceased 15 May 2025)

Category 4: Sponsorship

  • The member receives administrative support for his parliamentary work from two employees of Vos Amis Limited (investment advice, personal services and real estate)